

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-46 (Canceled)

47. (Currently Amended) A method for treating Parkinson's Disease,
~~comprising of treatment for a disease, wherein the disease is selected from the group~~
~~consisting of atherosclerosis, cardiovascular disease, diabetes, retinopathy, cataract~~
~~formation, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic~~
~~lateral sclerosis, 21 trisomy, and hypertension, wherein the method comprises~~
administering to a Parkinson's disease patient a replication defective, recombinant
adenovirus comprising a DNA sequence which encodes an intracellular CuZn
superoxide dismutase-1 (SOD-1), wherein the DNA sequence is under the control of a
signal enabling expression in a target cell,~~to a patient suffering from such a disease~~
and wherein said expression of said superoxide dismutase results in a treatment of
Parkinson's disease.

Claims 48-60 (Canceled)

61. (Previously Presented) The method of treatment according to claim 47,
wherein the DNA sequence is a cDNA sequence.

62. (Previously Presented) The method of treatment according to claim 61,
wherein the cDNA sequence encodes human intracellular CuZn superoxide dismutase-
1 (hSOD-1).

63. (Previously Presented) The method of treatment according to claim 47,

wherein the signal enabling expression in a target cell is a viral promoter.

64. (Previously Presented) The method of treatment according to claim 63, wherein the promoter is selected from the group consisting of the E1A, MLP, CMV and RSV-LTR promoters.

65. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus lacks regions of its genome which are necessary for replication in a target cell.

66. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus comprises ITR sequences and an encapsidation sequence, and wherein the E1 gene and at least one of the E2, E4 or L1-L5 genes are non-functional.

67. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus is of a type selected from the group consisting of human Ad 2, human Ad 5, and canine CAV-2.

68. (Previously Presented) The method of treatment according to claim 62, wherein the cDNA sequence encodes human intracellular CuZn superoxide dismutase-1 (hSOD1) under the control of an RSV-LTR promoter.

Claims 69-77 (Canceled)

78. (Previously Presented) The method of treatment according to claim 47, wherein the signal enabling expression in a target cell is a promoter permitting preponderant expression in the target cell.

79. (Previously Presented) The method of treatment according to claim 47, wherein the method comprises administering a cell infected with the replication

defective, recombinant adenovirus to the patient.

Claims 80-82 (Canceled)

83. (Currently Amended) The method of treatment ~~of any one of claims 66, 69-75~~ according to claim 66, wherein the adenovirus comprises ITR sequences and an encapsidation sequence, and wherein the E1 gene and at least one of the E4 or L1-L5 genes are non-functional.